PDF icon PDF herunterladen
J Neurol Surg A Cent Eur Neurosurg 2021; 82(06): 568-580
DOI: 10.1055/s-0041-1725954
Review Article

Clinical Efficacy and Safety Profile of Anterior Thalamic Stimulation for Intractable Epilepsy

Michał Sobstyl
1   Department of Neurosurgery, Institute of Psychiatry and Neurology, Warszawa, Poland
,
Angelika Stapińska-Syniec 
1   Department of Neurosurgery, Institute of Psychiatry and Neurology, Warszawa, Poland
,
Szczepan Iwański
2   2nd Department of Neurology, Institute of Psychiatry and Neurology, Warszawa, Poland
,
Marcin Rylski
3   Department of Neuroradiology, Institute of Psychiatry and Neurology, Warszawa, Poland
4   Department of Clinical Cytology, Centrum Medyczne Ksztalcenia Podyplomowego, Warszawa, Poland
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRefMedOne
  Lizenzen und Reprints
Preview

Abstract

Introduction Deep brain stimulation of the anterior nucleus of the thalamus (ANT DBS) is a neuromodulation therapy for patients with refractory partial seizures. The ANT is the structure of a limbic system with abundant neuronal connections to temporal and frontal brain regions that participate in seizure propagation circuitry.

State of the Art We have performed a literature search regarding the clinical efficacy of ANT DBS. We discuss the surgical technique of the implantation of DBS electrodes with special attention paid to the targeting methods of the ANT. Moreover, we present in detail the clinical efficacy of ANT DBS, with a special emphasis on the stimulation parameters, a stimulation mode, and polarity. We also report all adverse events and present the current limitations of ANT DBS.

Clinical Implications In general, the safety profile of DBS in intractable epilepsy patients is good, with a low rate of surgery, hardware-related, and stimulation-induced adverse events. No significant cognitive declines or worsening of depressive symptoms was noted. At long-term follow-up, the quality-of-life scores have improved. The limitations of ANT DBS studies include a limited number of patients treated and mostly open-label designs with only one double-blind, randomized multicenter trial. Most studies do not report the etiology of intractable epilepsy or they include nonhomogeneous groups of patients affected by intractable epilepsy. There are no guidelines for setting initial stimulation parameters. All the variables mentioned may have a profound impact on the final outcome.

Conclusions ANT DBS appears to be a safe and efficacious treatment, particularly in patients with refractory partial seizures (three-quarters of patients gained at least 50% seizure reduction after 5 years). ANT DBS reduces most effectively the seizures originating in the temporal and frontal lobes. The published results of ANT DBS highlight promise and hope for patients with intractable epilepsy.

Keywords

intractable epilepsy - anterior nucleus of the thalamus - deep brain stimulation - thalamic stimulation


Publikationsverlauf

Eingereicht: 02. Juli 2020

Angenommen: 16. Dezember 2020

Artikel online veröffentlicht:
14. Juni 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany